No specific information is available on the treatment of overdose with montelukast. In chronic asthma studies, montelukast has been administered at doses up to 200 mg/day to patients for 22 weeks and in short-term studies, up to 900 mg/day to patients for approximately 1 week without clinically important adverse experiences.
There have been reports of acute overdose in post-marketing and clinical studies with montelukast. These includes reports in adults and children with a dose as high as 1,000 mg (approximately 61 mg/kg in a 42-month old child). The clinical and laboratory findings observed were consistent with the safety profile in adults and paediatric patients. There were no adverse experiences in the majority of overdosage reports. The most frequently occurring adverse experiences were consistent with the safety profile of montelukast and included abdominal pain, somnolence, thirst, headache, vomiting and psychomotor hyperactivity.
It is not known whether montelukast is dialyzable by peritoneal or hemodialysis.